By James Swann
Medicare could have saved $910 million in 2011 by paying the lowest possible rate for certain clinical lab tests, according to a report from the Department of Health and Human Services Office of Inspector General released June 11.
The report, Comparing Lab Test Payment Rates: Medicare Could Achieve Substantial Savings (OEI-07-11-00010), said “Medicare could have saved $910 million, or 38 percent, in 2011 if it had paid the same rate as the lowest paying insurer surveyed for each lab test in each geographic location.”
OIG looked at payment rates for 20 clinical lab tests in 56 geographic regions and compared Medicare's payment rates against those of Medicaid and three fee-for-service Federal Employees Health Benefits (FEHB) plans.
Medicare paid 20 percent more for the 20 lab tests than Medicaid and between 18 percent and 30 percent more than the three FEHB plans.
The report said the Centers for Medicare & Medicaid Services has limited authority to revise payment rates for clinical lab tests and that congressional action is required for any major payment rate changes.
Medicaid and the FEHB plans, on the other hand, have more flexibility in establishing payment rates.
“For example, eight Medicaid plans and four local FEHB plans reported that technological changes (e.g., benchmarking payment rates for new tests to the actual cost of performing them) are taken into account when establishing payment rates,” the report said.
OIG recommended that CMS ask Congress to create lower payment rates for clinical lab tests. For example, congressional legislation could create demonstration programs to determine the value of lower payment rates, OIG said, or could allow CMS to make payment rate changes on a test-by-test basis.
OIG also recommended that CMS ask Congress to implement copays and deductibles for Medicare clinical lab tests. “The concept of beneficiary copayments and deductibles is used broadly for other types of services in Medicare; requiring them could lead to cost savings,” OIG said.
CMS neither agreed nor disagreed with the recommendations. The agency said it “is currently exploring whether it has the authority under the current statute to revise payments for clinical diagnostic laboratory services consistent with the OIG's recommendation.”
OIG asked CMS to indicate in its final management decision whether it agreed or disagreed with the recommendations.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).